Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

I. Khan, A. Kaempf, S. Raghuwanshi, M. Chesnokov, X. Zhang, Z. Wang, A. Domling, J. W. Tyner, C. Camacho, A. L. Gartel*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

4 Citations (Scopus)
25 Downloads (Pure)
Original languageEnglish
Article number128
Number of pages5
JournalBlood cancer journal
Volume13
Issue number1
DOIs
Publication statusPublished - Dec-2023

Cite this